mRNA Vaccines & Therapeutics Patent Landscape 2026
mRNA Vaccines & Therapeutics Patent Landscape in 2026
ModernaTX leads a heavily concentrated field where the five largest filers account for 37% of the top hundred applicants’ combined output, with academic institutions occupying three of the top four positions. The field is still expanding on a multi-year basis, though annual volume has eased from its 2022 peak and the most recent filing years are further understated by publication lag.
ModernaTX leads a field shaped by pharma-academic alliances
ModernaTX holds the top position with 2,123 patent families, nearly double the count of second-ranked Massachusetts Institute of Technology at 1,286 patent families — a gap that underscores the company’s strategy of building a broad proprietary platform rather than concentrating on narrow indications.
The top five filers — ModernaTX, MIT, The Broad Institute, Harvard, and Translate Bio — together represent 37% of the hundred largest filers’ combined total, a concentration level that signals meaningful but not absolute barriers: several challengers in the 200–700 family range retain room to maneuver on specific delivery or indication vectors.
| # | Applicant | Patent families | Share |
|---|---|---|---|
| 1 | ModernaTX Inc | 2,123 | |
| 2 | Massachusetts Institute of Technology | 1,286 | |
| 3 | The Broad Institute Inc | 1,190 | |
| 4 | PRESIDENT & FELLOWS OF HARVARD COLLEGE | 845 | |
| 5 | Translate Bio Inc | 734 | |
| 6 | Intellia Therapeutics Inc | 628 | |
| 7 | The Trustees of the University of Pennsylvania | 451 | |
| 8 | CRISPR Therapeutics AG | 345 | |
| 9 | Dyne Therapeutics Inc | 303 | |
| 10 | Pfizer Inc | 286 |
| # | Applicant | Patent families | Share |
|---|---|---|---|
| 11 | Ethris GmbH | 272 | |
| 12 | The Government of the United States of America | 249 | |
| 13 | GlaxoSmithKline Biologicals SA | 221 | |
| 14 | TRON – Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz | 215 | |
| 15 | REGENXBIO Inc | 207 | |
| 16 | Gilead Sciences Inc | 202 | |
| 17 | Acuitas Therapeutics Inc | 189 | |
| 18 | The Regents of the University of California | 187 | |
| 19 | Board of Regents, The University of Texas System | 185 | |
| 20 | Moderna Therapeutics Inc | 176 |
The presence of three major research universities in the top four positions is structurally significant: MIT, The Broad Institute, and Harvard generate foundational IP that commercial players license or co-develop, meaning the practical competitive moat is wider than any single applicant’s count suggests.
Filing counts for 2024 and 2025 are materially understated due to the 18–24 month patent publication lag; apparent softness in those years should not be read as a market slowdown. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
A 2022 surge shaped the field; nucleic-acid delivery chemistry anchors the technology mix
The filing trend and technology composition charts together reveal a field that accelerated sharply from 2020 to 2022 and has since settled at an elevated baseline, with the dominant IP clusters concentrated in medicinal preparations and genetic engineering.
Annual filing trend
Annual filings grew steadily from 986 in 2017 to a pronounced peak of 2,997 in 2022 — the year most reflective of post-pandemic mRNA platform investment — before easing to 2,589 in 2023 and 2,283 in 2024. The sharp drop in 2025 and near-zero 2026 values are publication-lag artefacts, not real declines; the three-year recent window sits 52% above the prior equivalent window, confirming continued multi-year expansion.
↗ Hover for values · click a bar to ask EurekaTechnology composition
Medicinal preparations (A61K) and microorganisms & genetic engineering (C12N) dominate the IPC mix, reflecting the dual nature of mRNA IP — formulation and delivery on one axis, sequence engineering and gene editing on the other. Peptides & proteins (C07K) and therapeutic activity (A61P) form a secondary cluster, while sugars & nucleic acids (C07H), enzyme testing (C12Q), and fermentation synthesis (C12P) represent sparser but technically adjacent branches.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Mucosal messenger RNA vaccine
The present invention is related to a mucosal mRNA vaccine. More specifically, the present invention relates to novel mucosal mRNA vaccine based on a peptide-conjugated, mRNA loaded nanoparticle with enhanced vaccine efficacy, and a method of preparing the same. (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Delivery of exogenous DNA sequences in a mammal | 6,494 |
| 2 | Induction of a protective immune response in a mam… | 5,316 |
| 3 | Recombinant DNA sequences, vectors containing them… | 2,203 |
| 4 | Method for dominant selection in eucaryotic cells | 2,148 |
| 5 | Expression of exogenous polynucleotide sequences i… | 1,906 |
| 6 | Delivery, engineering and optimization of systems,… | 1,479 |
| 7 | Generation of antibodies through lipid mediated DN… | 1,269 |
| 8 | Engineering and optimization of improved systems, … | 1,092 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents.
What the structure means for R&D strategy
Four structural features — lifecycle stage, concentration, ecosystem collaboration, and geographic footprint — define the strategic terrain for any team evaluating mRNA IP investment.
Growth stage with post-peak annual moderation
The field is classified as Growth: recent three-year filings sit 52% above the prior three-year window on a multi-year basis, confirming continued expansion. However, annual volume has eased from the 2022 peak of 2,997 filings, and publication lag further suppresses apparent 2024–2025 activity. Teams should treat the current moment as mid-growth, not saturation.
Lifecycle: GrowthTop five hold 37% of leading-filer output; mid-tier is accessible
The top five filers account for 37% of the hundred largest filers’ combined total, with ModernaTX’s 2,123 patent families creating a substantial lead over the next tier. Challengers ranked 6–20 — including Intellia Therapeutics, University of Pennsylvania, CRISPR Therapeutics, Dyne Therapeutics, and Pfizer — each hold between roughly 280 and 630 patent families, leaving meaningful space for focused differentiation in delivery mechanisms or specific disease indications.
High concentrationMIT–Broad–Harvard triangle dominates co-filing; BioNTech–TRON is the key industry-academic pair
The most active co-filing partnership is MIT and The Broad Institute at 731 shared filings, followed by Broad–Harvard at 443 and MIT–Harvard at 393. On the industry side, BioNTech and TRON (Translational Oncology at the University of Mainz) have co-filed 99 times, and Intellia Therapeutics co-files frequently with Regeneron Pharmaceuticals at 57. These alliances shape licensing landscapes and freedom-to-operate analysis for any entrant.
Dense academic networkUS-centric with strong PCT and EPO reach; Asia is underweighted relative to market size
The United States is the primary filing jurisdiction, followed by WIPO PCT and the EPO — the standard triad for global protection strategy. Australia and Canada rank fourth and fifth among jurisdictions. China and Japan filings are notably lower relative to their pharmaceutical market scale, suggesting either strategic restraint by Western applicants or an emerging opportunity for local players to build defensive positions in those markets.
US-led, global PCTGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| Massachusetts Institute of Technology | The Broad Institute Inc | 731 |
| The Broad Institute Inc | President & Fellows of Harvard College | 443 |
| Massachusetts Institute of Technology | President & Fellows of Harvard College | 393 |
| BioNTech SE | TRON – Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz | 99 |
| Intellia Therapeutics Inc | Regeneron Pharmaceuticals Inc | 57 |
| The Broad Institute Inc | Rutgers, The State University of New Jersey | 27 |
| President & Fellows of Harvard College | Rutgers, The State University of New Jersey | 27 |
| Massachusetts Institute of Technology | The University of Tokyo | 26 |
| The Broad Institute Inc | The University of Tokyo | 26 |
| Massachusetts Institute of Technology | Rutgers, The State University of New Jersey | 25 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
ModernaTX versus the academic vanguard: different strategies, overlapping IP
The top two positions are held by a commercial platform builder and a research university respectively, reflecting the dual engine — industry investment and academic discovery — that drives this field. Momentum data shows ModernaTX holding steady while BioNTech is accelerating sharply.
ModernaTX Inc
ModernaTX leads with 2,123 patent families, concentrated across genetic engineering (C12N 15), vaccine-related medicinal preparations (A61K 39), and nucleic-acid medicinal preparations (A61K 48). Its recent three-year filing pace shows a near-flat trajectory at +4% versus the prior period, indicating a mature but sustained platform-building posture rather than a surge or retreat.
families: 2,123BioNTech SE
BioNTech (appearing in the route matrix as BioNTech European stock company) filed 368 patent families in the most recent three-year window, representing a +144% increase versus the prior period — the strongest momentum among tracked applicants. Its technology emphasis centers on vaccine formulations (A61K 39), genetic engineering (C12N 15), and anti-infective therapeutic activity (A61P 31), consistent with its oncology and infectious-disease pipeline expansion.
families: tracked| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| ModernaTX Inc | 399 | ▬ +4% |
| Massachusetts Institute of Technology | 160 | ▼ -13% |
| The Broad Institute Inc | 158 | ▬ +3% |
| President & Fellows of Harvard College | 115 | ▼ -23% |
| BioNTech SE | 368 | ▲ +144% |
| Translate Bio Inc | 59 | ▼ -77% |
| Intellia Therapeutics Inc | 148 | ▼ -7% |
Under-served adjacent branches worth monitoring
Five IPC branches with lower filing share sit adjacent to the dominant mRNA platform clusters. Two carry plausible technical relevance and a realistic entry path for teams with complementary capabilities.
C07H · Sugars & nucleic acids chemistry
With 979 patent records and a 2% share of classified filings, C07H covers the chemical synthesis and modification of nucleotides and oligonucleotides — directly relevant to modified-nucleoside mRNA design, cap analogue engineering, and backbone chemistry. The relative sparsity suggests that deep chemical IP around nucleoside modifications remains less crowded than delivery or sequence engineering. Teams with medicinal chemistry or organic synthesis capabilities could build differentiated positions here, particularly around novel nucleoside analogues or cap structures that improve mRNA stability and immunogenicity.
Search this in Eureka →C12P · Fermentation & enzymatic synthesis
C12P accounts for 829 patent records at a 2% share, covering enzymatic and cell-free synthesis of biological macromolecules including mRNA itself. As in-vitro transcription (IVT) scale-up becomes a manufacturing bottleneck, IP around enzymatic synthesis processes, IVT enzyme engineering, and cell-free production systems is technically valuable but relatively sparse in this corpus. Organizations with bioprocess or synthetic biology expertise — particularly those focused on reducing manufacturing cost or improving RNA purity — may find this branch accessible relative to the crowded formulation and delivery space.
Search this in Eureka →How leading applicants differ by technology route
Strength of each leader across the main technology routes.
| Player | C12N 15 · Microorganisms & genetic engineering | A61K 39 · Medicinal preparations | A61K 48 · Medicinal preparations | C07K 14 · Peptides & proteins | A61K 9 · Medicinal preparations |
|---|---|---|---|---|---|
| ModernaTX Inc | Strong · 828 | Strong · 775 | Strong · 704 | Moderate · 390 | Strong · 691 |
| Massachusetts Institute of Technology | Strong · 884 | Absent | Moderate · 315 | Absent | Emerging · 82 |
| The Broad Institute Inc | Strong · 812 | Absent | Moderate · 204 | Emerging · 74 | Absent |
| BioNTech SE | Strong · 310 | Strong · 445 | Absent | Moderate · 108 | Moderate · 162 |
| Translate Bio Inc | Strong · 320 | Absent | Strong · 314 | Absent | Strong · 303 |
| President & Fellows of Harvard College | Strong · 583 | Absent | Moderate · 138 | Emerging · 74 | Absent |
Frequently asked questions
ModernaTX Inc leads with 2,123 patent families, nearly double the count of the second-ranked filer, Massachusetts Institute of Technology, which holds 1,286 patent families. The Broad Institute ranks third at 1,190 patent families.
The top five filers account for 37% of the hundred largest filers’ combined total. The leading tier comprises ModernaTX, MIT, The Broad Institute, Harvard, and Translate Bio. A mid-tier of applicants holding roughly 280–630 patent families each — including Intellia Therapeutics, University of Pennsylvania, CRISPR Therapeutics, Dyne Therapeutics, and Pfizer — retains meaningful room to differentiate on specific routes.
On a multi-year basis, yes: recent three-year filings are 52% above the prior equivalent window, placing the field in a Growth lifecycle stage. Annual volume peaked in 2022 at 2,997 filings and has moderated since, but 2024 and 2025 counts are materially understated by the 18–24 month publication lag and should not be read as a real contraction.
The United States is the primary filing jurisdiction, followed by WIPO PCT and the EPO — the standard triad for global protection. Australia and Canada rank fourth and fifth. China and Japan show notably lower filing volumes relative to their pharmaceutical market scale.
The most heavily cited document in scope covers delivery of exogenous DNA sequences in mammals, with 6,494 citations. The second most cited covers induction of a protective immune response in mammals at 5,316 citations. These foundational references on nucleic-acid delivery and immunization underpin much of the field’s current IP landscape.
The MIT–Broad Institute pair is the most active co-filing partnership with 731 shared filings. Broad–Harvard follows at 443 and MIT–Harvard at 393, forming a dominant academic triangle. On the industry-academic side, BioNTech and TRON (Translational Oncology, University of Mainz) have 99 co-filings, and Intellia Therapeutics and Regeneron Pharmaceuticals have co-filed 57 times.
Ready to map your own mRNA patent landscape?
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.